ReviewJACC. Asia2025
Decoding Bleeding Risks and Survival in Patients Undergoing Percutaneous Coronary Intervention on Antiplatelet Therapy.
Review in JACC. Asia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-analysis and external validation of a risk model for gastrointestinal bleeding after percutaneous coronary intervention.BMC medicine · 2025Pooled it
- Antithrombotic Therapy After PCI in High-Risk Cardiovascular Patients: Navigating Complexity Beyond Guidelines.Journal of clinical medicine · 2026Review
- Interpretable machine learning for predicting in-hospital bleeding after PCI in patients with diabetes and acute coronary syndrome: a retrospective cohort study.BMC cardiovascular disorders · 2026Article
- Toward an integrated risk paradigm: personalizing antithrombotic therapy for coronary heart disease with gastrointestinal bleeding.Frontiers in cardiovascular medicine · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This comprehensive review focuses on bleeding risk and outcomes in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) with antiplatelet therapy. Bleeding prevalence varies widely, ranging from 1% to 10% in clinical trials and 2.8% to 11% in real-world studies, with a significant impact on mortality. The Academic Research Consortium for High Bleeding Risk criteria are well-validated, classifying approximately 50% of patients as high bleeding risk, who subsequently experience higher post-PCI bleeding rates. Key risk factors include advanced age, chronic kidney disease, and multiple comorbidities. This review also explores bleeding event definitions, risk stratification methods, and the clinical consequences of bleeding. The strong association between bleeding and mortality after PCI underscores the importance of vigilant monitoring and tailored management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.